In acute myeloid leukemia (AML), RIPK3 signaling might be epigenetically repressed in leukemic cells isolated from a subgroup of AML patients such as AML with RUNX1-ETO or FLT3-ITD mutations (Hockendorf et al., 2016). The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.